InterCure Ltd. Form 6-K Summary
Business Context and Reporting Period
InterCure Ltd., an Israeli foreign private issuer, filed Form 6-K on November 16, 2022, covering the month of November 2022. The filing includes unaudited interim consolidated financial statements and management’s discussion and analysis for the period ended September 30, 2022.
Financial Metrics
The provided filing text does not include the financial statements or detailed management discussion. Accordingly, revenue, profit, cash flow, margins, debt, liquidity, and other financial metrics cannot be determined from the available text.
Material Changes Versus Prior Period
The filing identifies a press release titled “InterCure Announces Record Breaking Third Quarter Financial Results,” but the provided text does not include the underlying results or comparisons with the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, risk factors, contingencies, or unusual items are described in the available filing text. The filing references management’s discussion and analysis, but that exhibit was not provided in detail.
Important Facts to Verify
- Review Exhibit 99.1 for September 30, 2022 revenue, profitability, cash flow, balance-sheet, debt, and liquidity data.
- Review Exhibit 99.2 for management’s explanations of operating results, material changes, liquidity, capital resources, risks, and outlook.
- Review Exhibit 99.4 for the reported third-quarter results and any forward-looking statements.
- Confirm the scope and accounting treatment of the “record breaking” results against the prior-year and sequential periods.
- Note that the interim financial statements are identified as unaudited.